UX Data Sciences acquired by ChroMedX

24 May 2018
Client work


On May 24, 2018, ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (Frankfurt: EIY2) announced the closing of its previously announced acquisition of UX Data Sciences Corp. ("UXD"). ChroMedX issued common shares valued at $5.5 million to the shareholders of UXD. With this transaction, UXD became a wholly-owned subsidiary of ChroMedX. 

ChroMedX Corp. is a medical technology company focused on the development of novel, handheld medical devices for diagnostic testing. UXD is an Ottawa, Ontario-based medical technology and data science company developing products and systems solutions for improving, tracking and monitoring patient compliance and medication adherence.

Gowling WLG advised UXD in this transaction with a team that included Garrett Hamel and Lorraine Mastersmith (corporate and securities).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Mergers & Acquisitions, Corporate Commercial

Related Insights & Resources

View all insights Related Insights & Resources
Client work
22 November 2021 TickTrade acquired by smartTrade creating global leader in SaaS FX trading platforms
Client work
19 November 2021 Mineros S.A. becomes first Latin American company to list shares on TSX, closes Canadian IPO and concurrent Colombian public offering
Client work
15 November 2021 Atmofizer Technologies Inc. closes RTO with Vaxxinator Enterprises Inc.

Team

Download or print PDF